Discussion about this post

User's avatar
Eric Rosen's avatar

Thanks. Hearing about a new med that has fewer side effects. Do you know it?

Expand full comment
Neural Foundry's avatar

The juxtaposition of the big tech earnings section with the Lilly mention buried in Other Headlines misses how significant the pharma AI convergance really is. While everyone's focused on Alphabet's cloud growth and Meta's AI spending concerns, Lilly is quietly building computational drug discovery infrastructure that could generate more durable moats than consumer AI applications. The Zepbound and Mounjaro sales surge isn't just about current metabolic therapies, it's funding the next generation pipline through those GPU clusters we're seeing them deploy.

Expand full comment

No posts

Ready for more?